Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Eyes Xeljanz Expansion To Ulcerative Colitis

This article was originally published in The Pink Sheet Daily

Executive Summary

Two Phase III trials testing the oral JAK inhibitor in ulcerative colitis met their primary endpoints, but Pfizer is awaiting the results of another Phase III maintenance study before filing for a label extension.

You may also be interested in...



Pfizer's Xeljanz: The Slow Road To Blockbuster Status

The oral pill, perhaps best known to investors for failing to live up to initial expectations in rheumatoid arthritis, has found its groove – and new opportunities in psoriatic arthritis and ulcerative colitis are on the horizon.

J&J's Next Immunology Act Centers On Nipocalimab For Autoantibody-Driven Diseases

The company has ramped up a broad R&D program for the FcRn inhibitor in 11 autoantibody-driven disease areas.

Neurocrine Gains Clinical-Stage Schizophrenia Candidates Returned To Sosei By AbbVie

Deal Snapshot: Neurocrine expanded its pipeline with rights to subtype-selective muscarinic M4, M1 and dual M1/M4 receptor agonists discovered by Sosei.

Topics

Related Companies

UsernamePublicRestriction

Register

PS078936

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel